Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child.
The maximum tolerated single dose of intravenous iron infusion and iron pharmacokinetics are not known in children and not clear in adults. The case reported here is of a child given a large dose of intravenous iron sucrose (16 mg/kg) over 3 hours, who subsequently developed features of systemic iron toxicity. A TDM consultant discusses the case in the context of toxicokinetic analysis. Because the maximum tolerated dose and pharmacokinetics of intravenous iron preparations are not known, their use in both adults and children should still be undertaken with caution.
Wood
David Michael
DM
Department of General Medicine, St. George's University of London, London, UK. dwood@sghms.ac.uk
Thomson
Alison H
AH
Lawes
Matthew
M
Jones
Alison Linda
AL
Dargan
Paul Ivor
PI
D018798:Anemia, Iron-Deficiency / Q000175:diagnosis / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D002675:Child, Preschool; D003676:Deferoxamine / Q000627:therapeutic use; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077605:Ferric Oxide, Saccharated; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy; D005937:Glucaric Acid; D006801:Humans; D007262:Infusions, Intravenous; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy; D008297:Male; D017262:Siderophores / Q000627:therapeutic use; D016896:Treatment Outcome
D005290:Ferric Compounds; D017262:Siderophores; D000077605:Ferric Oxide, Saccharated; D003676:Deferoxamine; D005937:Glucaric Acid